ES2345573T3 - Utilizacion de ranolazina para la preparacion de un medicamento para el tratamiento de las posdespolarizaciones precoces (ead). - Google Patents

Utilizacion de ranolazina para la preparacion de un medicamento para el tratamiento de las posdespolarizaciones precoces (ead). Download PDF

Info

Publication number
ES2345573T3
ES2345573T3 ES08004276T ES08004276T ES2345573T3 ES 2345573 T3 ES2345573 T3 ES 2345573T3 ES 08004276 T ES08004276 T ES 08004276T ES 08004276 T ES08004276 T ES 08004276T ES 2345573 T3 ES2345573 T3 ES 2345573T3
Authority
ES
Spain
Prior art keywords
ranolazine
compound
use according
administration
intended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08004276T
Other languages
English (en)
Spanish (es)
Inventor
Luiz Belardinelli
Charles Antzelevitch
Brent Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc
Application granted granted Critical
Publication of ES2345573T3 publication Critical patent/ES2345573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES08004276T 2002-04-04 2003-04-04 Utilizacion de ranolazina para la preparacion de un medicamento para el tratamiento de las posdespolarizaciones precoces (ead). Expired - Lifetime ES2345573T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US37015002P 2002-04-04 2002-04-04
US370150P 2002-04-04
US40829202P 2002-09-05 2002-09-05
US408292P 2002-09-05
US42258902P 2002-10-30 2002-10-30
US422589P 2002-10-30

Publications (1)

Publication Number Publication Date
ES2345573T3 true ES2345573T3 (es) 2010-09-27

Family

ID=29255318

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08004276T Expired - Lifetime ES2345573T3 (es) 2002-04-04 2003-04-04 Utilizacion de ranolazina para la preparacion de un medicamento para el tratamiento de las posdespolarizaciones precoces (ead).
ES03723907T Expired - Lifetime ES2304507T3 (es) 2002-04-04 2003-04-04 Utilizacion de ranolazina para la preparacion de un medicamento destinado al tratamiento de las arritmias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03723907T Expired - Lifetime ES2304507T3 (es) 2002-04-04 2003-04-04 Utilizacion de ranolazina para la preparacion de un medicamento destinado al tratamiento de las arritmias.

Country Status (19)

Country Link
US (2) US20030220344A1 (enExample)
EP (3) EP1930007B1 (enExample)
JP (1) JP4608217B2 (enExample)
KR (2) KR20100119804A (enExample)
CN (2) CN101843619A (enExample)
AT (2) ATE397932T1 (enExample)
AU (3) AU2003230810B2 (enExample)
CA (1) CA2481192C (enExample)
CY (1) CY1110400T1 (enExample)
DE (2) DE60332975D1 (enExample)
DK (2) DK1930007T3 (enExample)
ES (2) ES2345573T3 (enExample)
IL (1) IL197406A0 (enExample)
MX (1) MXPA04009637A (enExample)
NO (1) NO330953B1 (enExample)
NZ (1) NZ535610A (enExample)
PT (2) PT1490066E (enExample)
SI (2) SI1930007T1 (enExample)
WO (1) WO2003086401A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
SG156681A1 (en) * 2004-11-09 2009-11-26 Cv Therapeutics Inc Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
KR20070093988A (ko) * 2005-01-06 2007-09-19 씨브이 쎄러퓨틱스, 인코포레이티드 라놀라진 함유 서방성 약제학적 제형물
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
WO2010028173A2 (en) * 2008-09-04 2010-03-11 Gilead Palo Alto, Inc. Method of treating atrial fibrillation
WO2010074807A1 (en) * 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201407322QA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014027262A2 (en) * 2012-08-14 2014-02-20 Mahesh Kandula Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en) 2012-09-08 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
CN105611931A (zh) * 2013-08-01 2016-05-25 吉利德科学公司 治疗长qt综合征的化合物和方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
KR101617683B1 (ko) * 2015-01-09 2016-05-03 연세대학교 산학협력단 부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
CN116808039A (zh) * 2023-03-27 2023-09-29 河南中医药大学第一附属医院 青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) * 2023-07-06 2025-01-09 The General Hospital Corporation Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
JPH03141258A (ja) * 1989-10-25 1991-06-17 Kowa Co 新規なピペラジン誘導体
ATE211135T1 (de) * 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
WO2001089554A2 (en) * 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
EP2198866A1 (en) 2010-06-23
AU2011202135A1 (en) 2011-05-26
PT1930007E (pt) 2010-08-17
EP1930007B1 (en) 2010-06-09
US20100004255A1 (en) 2010-01-07
MXPA04009637A (es) 2005-07-14
DK1490066T3 (da) 2008-10-13
AU2003230810B2 (en) 2009-02-26
SI1490066T1 (sl) 2008-10-31
SI1930007T1 (sl) 2010-08-31
EP1490066A1 (en) 2004-12-29
CN101843619A (zh) 2010-09-29
CA2481192A1 (en) 2003-10-23
PT1490066E (pt) 2008-07-22
AU2009201065A1 (en) 2009-04-09
DK1930007T3 (da) 2010-08-30
KR20040099395A (ko) 2004-11-26
CY1110400T1 (el) 2015-04-29
KR20100119804A (ko) 2010-11-10
NO20044783L (no) 2004-11-03
AU2003230810A1 (en) 2003-10-27
DE60321550D1 (de) 2008-07-24
IL197406A0 (en) 2011-07-31
AU2009201065B2 (en) 2011-07-21
US20030220344A1 (en) 2003-11-27
ES2304507T3 (es) 2008-10-16
HK1120390A1 (en) 2009-04-03
CN100548300C (zh) 2009-10-14
EP1930007A1 (en) 2008-06-11
NO330953B1 (no) 2011-08-22
WO2003086401A1 (en) 2003-10-23
ATE397932T1 (de) 2008-07-15
JP2005528393A (ja) 2005-09-22
CA2481192C (en) 2012-07-03
JP4608217B2 (ja) 2011-01-12
DE60332975D1 (de) 2010-07-22
NZ535610A (en) 2006-05-26
CN1646127A (zh) 2005-07-27
ATE470445T1 (de) 2010-06-15
EP1490066B1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
ES2345573T3 (es) Utilizacion de ranolazina para la preparacion de un medicamento para el tratamiento de las posdespolarizaciones precoces (ead).
ES2540093T3 (es) Método para tratar la fibrilación auricular
ES2357801T3 (es) Agente terapéutico para trastorno queratoconjuntival.
ES2580108T3 (es) Compuestos de isoquinolina
US20120046299A1 (en) Method of treating arrhythmias
JP2010514696A (ja) 心血管症状の低減
KR102723194B1 (ko) Cftr 조절제 및 이의 사용 방법
CN102821765A (zh) 改良神经传导速度的方法和组合物
JP2018528251A (ja) 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ
WO2015192672A1 (zh) 苯并呋喃类衍生物、其制备方法和应用
ES2389872T3 (es) Composiciones farmacéuticas basadas en corticosteroides y en antagonistas del receptor B2 de cininas, y su uso
JP2001151742A (ja) アニリド誘導体及びそれを含有する抗不整脈剤
ES2861502T3 (es) Anestesia y analgesia locales y regionales
ZA200407972B (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
HK1145438A (en) Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias
AU2004222137A1 (en) 2-(Butyl-1-sulfonylamino)-N-(1(R)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
ES2634102T3 (es) Derivados de benzofurano fluorados
WO2000010605A2 (en) Preventives or remedies for eye circulatory failure
JPS63270625A (ja) 抗アレルギ−点眼剤
KR20080074128A (ko) 각결막 장애 치료제
JPWO2000010605A1 (ja) 眼循環障害の予防または治療剤
CN107286147A (zh) N‑[5‑（1,2,4‑三唑‑1‑基）噻唑‑2‑基]吗啉基酰胺及其医药用途
CN105873611A (zh) 利用pde4调节剂治疗病毒性疾病的组合物和方法